Colorectal cancer
Not recruitingA study of futibatinib combined with tislelizumab, fluorouracil, calcium folinate, and oxaliplatin as first-line treatment for patients with colorectal cancer
A study of futibatinib combined with tislelizumab, fluorouracil, calcium folinate, and oxaliplatin as first-line treatment for patients with colorectal cancer
- Disease:Colorectal cancer
- Substances:FluorouracilFutibatinib+3
Germany- Participants:18–64 years · 65+ years
- Substances:Fluorouracil
- Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH












